St. Jude Medical, Inc. STJ, a global medical device company, today
announced enrollment of the first patient in the EnligHTN III trial. This
study will evaluate the safety and performance of the new second-generation
EnligHTN^™ Renal Denervation System in patients with drug-resistant,
uncontrolled hypertension.
The next-generation system utilizes the proven multi-electrode catheter paired
with a new generator that features a high-tech, icon-friendly, touch screen
user interface that provides simultaneous ablations using four electrodes.
This advancement reduces total ablation time from approximately 24 minutes to
four minutes. With its unique non-occlusive basket design, each placement of
the ablation catheter using the EnligHTN system administers a predictable
treatment pattern while allowing for continuous blood flow to the kidney
throughout the procedure. Additionally, the new second-generation EnligHTN
generator allows physicians to easily view and record procedure information.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in